Publication:
Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis

Simple item page
dc.contributor.authorDİRESKENELİ, RAFİ HANER
dc.contributor.authorsInanc, N.; Dalkilic, E.; Kamali, S.; Kasapoglu-Gunal, E.; Elbir, Y.; Direskeneli, H.; Inanc, M.
dc.date.accessioned2022-03-12T17:33:03Z
dc.date.available2022-03-12T17:33:03Z
dc.date.issued2007
dc.description.abstractOur aim is to assess the prevalence and associated clinical features of anti-CCP (cyclic citrullinated peptide) antibodies for RF (rheumatoid factor)-positive and RF-negative rheumatoid arthritis (RA) and psoriatic arthritis (PsA). In a prospective, cross-sectional, multi-centre study, we determined the titres of anti-CCP antibodies in 208 RA patients (129 RF-positive, 79 RF-negative), 56 PsA patients and 39 healthy controls (HC). Clinical parameters including disease activity (disease activity score 28-DAS28), physical disability (health assessment questionnaire-HAQ), functional capacity (functional class) and radiological erosions were investigated in patients with RA. In PsA patients, clinical and radiological features were determined. Anti-CCP2 antibodies were measured using a second-generation anti-CCP enzyme-linked immunosorbent assay (Euro-Diagnostica, Netherlands). One-hundred four of 129 RF-positive RA (81%), 16 of 79 RF-negative RA (20%), seven of 56 PsA patients (12.5%) and none of the HC had anti-CCP antibodies. RA patients with anti-CCP antibodies had significantly higher disease activity, greater loss of function and more frequent erosive disease than anti-CCP antibody-negative group. In subgroup analysis, anti-CCP antibodies in RF-negative patients were also associated with erosive disease. All PsA patients with anti-CCP antibodies had symmetric arthritis with higher number of swollen joints. The prevalence of anti-CCP antibodies in RF-positive RA patients was significantly higher than in RF-negative RA and PsA patients. Anti-CCP antibodies were also associated with erosive disease in RF-negative RA patients. Both anti-CCP and RF tests were negative in 30% of the patients. Anti-CCP positivity was a frequent finding in PsA and associated with symmetrical polyarthritis.
dc.identifier.doi10.1007/s10067-006-0214-5
dc.identifier.eissn1434-9949
dc.identifier.issn0770-3198
dc.identifier.pubmed16538391
dc.identifier.urihttps://hdl.handle.net/11424/228760
dc.identifier.wosWOS:000243032100005
dc.language.isoeng
dc.publisherSPRINGER LONDON LTD
dc.relation.ispartofCLINICAL RHEUMATOLOGY
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectanti-CCP antibodies
dc.subjectpsoriatic arthritis
dc.subjectrheumatoid arthritis
dc.subjectrheumatoid factor
dc.subjectCITRULLINATED PEPTIDE ANTIBODIES
dc.subjectANTIKERATIN ANTIBODIES
dc.subjectPROGNOSTIC VALUE
dc.subjectDIAGNOSTIC-VALUE
dc.subjectAUTOANTIBODIES
dc.subjectPROGRESSION
dc.subjectASSOCIATIONS
dc.subjectDISEASE
dc.subjectCLASSIFICATION
dc.subjectCRITERIA
dc.titleAnti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis
dc.typearticle
dspace.entity.typePublication
local.avesis.idfe4669ea-3750-4e8f-a571-321172fc379a
local.import.packageSS17
local.indexed.atWOS
local.indexed.atSCOPUS
local.journal.numberofpages7
oaire.citation.endPage23
oaire.citation.issue1
oaire.citation.startPage17
oaire.citation.titleCLINICAL RHEUMATOLOGY
oaire.citation.volume26
relation.isAuthorOfPublication07a34d26-21f3-475d-bd36-152d6c659370
relation.isAuthorOfPublication.latestForDiscovery07a34d26-21f3-475d-bd36-152d6c659370

Files

Collections

Research Outputs